Virus infections in tumors pave the way for tumor-directed DC-vaccines.
Effective treatment of solid cancers by tumor-directed DC-vaccines still remains a challenge in clinical oncology. For therapeutic success, knock-down of tumor-specific tolerance appears mandatory before a potent tumor-specific cytotoxic T-cell response can be triggered by DC-vaccinations. Evidence is emerging that lytic virus infection in tumors can provide valuable help.
Department of Gastroenterology, Hepatology and Endocrinology; Medical School Hannover; Hannover, Germany.
Norman
N
Woller
Florian
F
Kühnel
Stefan
S
Kubicka